Orionis Biosciences Announces Strategic Collaboration with Novartis to Discover and Develop Molecular Glue Medicines
The collaboration will leverage Orionis’s advanced Allo‑Glue™ platform and its AI‑driven discovery engine
Orionis Biosciences, a privately held, clinical-stage life sciences company pioneering proximity-induced therapeutic modalities, today announced a multi-year collaboration with Novartis to discover and design molecular glue drugs for challenging therapeutic targets across multiple disease areas. The collaboration expands the existing relationship between the companies and reflects a shared commitment to unlock the full value of induced proximity approaches in drug development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610224927/en/ CEO Niko Kley, pictured with Chief Data Scientist Riccardo Sabatini and Chief Strategy Officer Giulio Draetta
Under the terms of the agreement, Novartis and Orionis will use Orionis’s Allo-Glue™ platform, together with its AI-driven discovery engine, to accelerate target and ligase profiling and molecular glue optimization. These integrated capabilities enable the systematic discovery of small molecule glues that modulate therapeutic targets through induced proximity mechanisms. Orionis will receive an upfront payment of USD 40 million and is eligible to receive research, development, and commercial milestone payments of up to USD 1.4 billion, in addition to tiered royalties on net sales of collaboration products.
